| Document |
Document Title |
|
WO/1996/026193A1 |
Phenyldiketone derivatives have the formula (I), in which the substituents have the following meanings: L, M are hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C1-C4 alkoxy optionally substituted by 1 to 5 halogen atoms or C1-C4 al...
|
|
WO/1996/025407A2 |
A process for producing salts of 3-isopropyl-2,1,3-benzothiadiazine-4-on-2,2-dioxide of general formula (I) (R1-R4 = H, lower alkyl, lower hydroxyalkyl) by reacting bentazone (IIa) in an organic solvent with an amine (IIIa), reacting ben...
|
|
WO/1996/024580A1 |
There are disclosed novel compounds of general formula (I) which compounds of formula (I) promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the prod...
|
|
WO/1996/022690A1 |
Plant-protecting mixtures of active ingredients having a synergistically increased action, wherein component (I) is a compound having a plant-immunizing action of formula (I), in which Z is CN, COOH or a salt thereof, CO-OC1-C4alkyl or C...
|
|
WO/1996/021435A1 |
Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram as well as with improved selectivity with regard to PDE III inhibition. In cert...
|
|
WO/1996/019995A1 |
This invention relates to derivatives of 4,4-(disubstituted)cyclohexan-1-ones and related compounds which are useful for treating allergic and inflammatory diseases.
|
|
WO/1996/019988A1 |
The present invention relates to novel 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhib...
|
|
WO/1996/019990A1 |
The present invention relates to novel 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and f...
|
|
WO/1996/020158A1 |
This invention relates to derivatives of 3,3-(disubstituted)cyclohexan-1-one monomers and related compounds which are useful for treating allergic and inflammatory diseases.
|
|
WO/1996/019467A1 |
The present invention is directed to compounds corresponding to formula (I), wherein R represents -Br, -Cl, -OCH1, -SCN, -OCH2SCN, -SCH2SCN, -OCH2CH2SCN, -SCH2CH2SCN, (a), (b) or (c); Y represents -Br, -Cl, -OCH1, -SCN, -OCH2SCN, -SCH2SC...
|
|
WO/1996/017825A1 |
Described are carboxylic acid amides of formula (I), as well as their use as pesticides, wherein A1 is hydrogen or alkyl; A2 is hydrogen or alkyl; A3 is hydrogen, alkyl or cyano; Ar1 is in either case optionally substituted arylene or he...
|
|
WO/1996/017831A1 |
Disclosed are compounds of formula I, in which the substituents and symbols have the meanings indicated in the description. These compounds are novel 5-HT1A-agonists and 'alpha'1-adrenoceptor blockers.
|
|
WO/1996/016952A1 |
2-Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
|
|
WO/1996/016649A1 |
2-Heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
|
|
WO/1996/016950A1 |
A HIV-1 protease inhibitor which includes an N-terminal cycle (A) or a C-terminal cycle (B) or both cycles (A) and (B) wherein Y is selected from side chains of Asn or Ile or Val or Glu and alkyl of 1-6 carbon atoms inclusive of linear o...
|
|
WO/1996/016954A1 |
Compounds of formula (I), wherein A is a 5-membered optionally substituted, heteroaryl group comprising at least one hetero atom selected from nitrogen, sulfur and oxygen, which is optionally substituted by one or more of the group R2; R...
|
|
WO/1996/016951A1 |
Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
|
|
WO/1996/016052A2 |
Disclosed are compounds of formula (I), wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1 and Ar2 independently represent aryl groups; and Y is hydrogen; o...
|
|
WO/1996/011918A1 |
N3S2 chelating ligands of formula (1) in which R, R1, R2, and n are as defined in claim 1, can be chelated to a radiodetectable element, Tc or Re, and are useful for radiolabelling peptides. A group of peptides especially useful are soma...
|
|
WO/1996/011906A1 |
The invention relates to a process for the preparation of substituted 3-aminobenzonitriles of formula (I) in which: R is hydrogen or C1-C12alkyl, C3-C8cycloalkyl, COR1, C1-C8alkoxyalkyl, C1-C6hydroxyalkyl, C1-C8aminoalkyl, C1-C8alkyl-NH(...
|
|
WO/1996/011183A1 |
The present invention relates to oxime ethers of general formula (I) and to their isomers and isomer mixtures which are possible in which (a) X is an N atom and Y is an oxygen atom or NH, or (b) X is CH and Y is an oxygen atom, in which ...
|
|
WO/1996/009296A1 |
A novel arylthiadiazole derivative represented by general formula (I) and useful for preventive or therapeutic treatment of human viral infection, or salts thereof, and an antiviral agent containing the same, wherein R1, R2 and R3 repres...
|
|
WO/1996/009301A1 |
A process for producing an N-biphenylmethylthiadiazoline derivative (7) according to the reaction scheme (I) in an industrially advantageous manner.
|
|
WO/1996/006072A1 |
Compounds of formula (I) are suitable for controlling and preventing infestation by micro-organisms, insects and acarina on plants and their possible isomers and mixtures of isomers, wherein (a) X is CH2F or CHF2, Y is CH and Z is OCH3, ...
|
|
WO/1996/005185A1 |
The present invention relates to novel alkylamino derivatives of formula (I). These compounds exhibit a high selectivity and a high affinity for sigma 2 receptor and therefore are useful in the treatment of central nervous system disorde...
|
|
WO/1996/004239A1 |
New N-alkoxy-amidine derivatives having the formula (I) are disclosed, as well as a process for preparing the same and their use as pesticides. Also disclosed are new intermediate products and a process for preparing the same.
|
|
WO/1996/003380A1 |
The present invention relates to compounds of formula (I), wherein A is an optionally substituted phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl having at least two adjacent ring ...
|
|
WO/1996/002249A1 |
The use is disclosed of thiazole and thiadiazole compounds having the formula (I), in which R1, A, B and Ar have the meanings given in the description. These compounds have a high affinity to the dopamine D3 receptor and are therefore us...
|
|
WO/1996/002523A1 |
The invention concerns novel substituted aryliminoheterocyclic rings of the general formula (I), (I), in which A stands for oxygen, sulphur or the grouping N-R1, wherein R1 stands for hydrogen or in each case optionally substituted alkyl...
|
|
WO/1996/001814A1 |
Compounds of formula (I), in which R1 is a substituent bonded via a carbon atom, R4 is a substituent, R2 and R3 are hydrogen or substituents and X is O, S, SO or SO2, are suitable as herbicides.
|
|
WO/1996/000218A1 |
Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess similar or improved PDE IV inhibition as compared to rolipram, with improved selectivity with regard to, e.g., PDE III inhibition. Preferred compo...
|
|
WO/1995/035275A1 |
Compounds of general formula (II) wherein X is a hydroxamic or carboxylic acid group, Y is carbonyl or sulphonyl and R1 and R2 are as defined in the claims, are matrix metalloproteinase inhibitors.
|
|
WO/1995/035276A1 |
Compounds of general formula (II), wherein X is a hydroxamic or carboxylic acid group, Y is sulphonyl and R1 and R2 as defined in the claims are matrix metalloproteinase inhibitors.
|
|
WO/1995/033491A1 |
Novel biotin amide analogs that are useful for targetting therapeutic and imaging agents to sites of infection and tumors in vivo are disclosed.
|
|
WO/1995/032192A1 |
The present invention provides aromatic amine substituted metal chelating compounds of formula (I) in which the variables are as defined in the claims, chelates and chelate-targeting moiety conjugates formed from the chelating compounds,...
|
|
WO/1995/032193A1 |
The invention relates to novel substituted thiadiazolines of general formula (I) in which R1, R2 and R3 have the meanings given in the description, process for producing them and their use as herbicides.
|
|
WO/1995/031198A1 |
Compounds of formula (I) wherein Thi is thiadiazolyl or thiadiazolyl substituted with alcoxy, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1-difluoroethyl, halo, alkyl, cycloalkyl, hydroxyalkyl, or alkoxyalkyl; Y is alkylene bridge o...
|
|
WO/1995/030661A1 |
The invention relates to novel substituted aromatic thiocarboxylic acid amides of general formula (I) in which R1, R2 and R3 are hydrogen or various substituents and Z is possibly substituted monocyclic or bicyclic, saturated or unsatura...
|
|
WO/1995/029925A1 |
A compound consisting essentially of a multidentade ligand including at least two thioether groups for being complexed to Rhodium-105 in specific activities that are sufficiently high for use in formulating therapeutic 105Rh-radiopharmac...
|
|
WO/1995/029905A1 |
The invention relates to novel alkyl sulphinyl and alkyl sulphonyl-1,2,4-thiadiazolyloxy acetamides of formula (I) in which n is the numbers 1 or 2, R1 is hydrogen or possibly substituted alkyl, alkenyl, alkinyl or aralkyl, R2 is possibl...
|
|
WO/1995/027692A1 |
Novel compounds for formula (I) are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; these compounds are also u...
|
|
WO/1995/026956A1 |
A compound represented by general formula (I) or a salt thereof, a process for producing the same, an intermediate for the production thereof, and a bactericide containing the same as the active ingredient wherein R1 represents optionall...
|
|
WO/1995/024403A1 |
A compound of formula (I), or a salt thereof, wherein n is 0, 1 or 2; and R is a group of formulae (II) to (XXI), wherein: the S(O)nCH2CH2CH=CF2 group is at least one of R1 (when attached to a carbon atom), R2, R3, R4, R5 or R6; R1 (when...
|
|
WO/1995/024186A1 |
Combinatorial libraries are disclosed which are represented by the formula (I): (T'-L)q- S -C(O)-L'-II' wherein: S is a solid support; T'-L- is an identifier residue; and -L'-II' is a ligand/linker residue. These libraries contain aryl s...
|
|
WO/1995/022523A1 |
A cyclic nitrogenous compound represented by general formula (1) and a herbicide containing the same, exhibiting a high herbicidal activity in a small dose, and having crop selectivity: wherein R1 represents alkyl; R represents hydgrogen...
|
|
WO/1995/021526A1 |
New and known 1,3,2-benzodithiazol-1-oxides having the formula (I) are disclosed, as well as their preparation and use for preventing technical materials from being affected by micro-organisms.
|
|
WO/1995/021837A1 |
Mono- or dipotassium salt of 2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl-1,3
,4-thiadiazolin-2-ylidene]aminocarbonyl]-1-cyclopentenecarbo
xylic acid, a medicinal composition containing the salt, the use of the salt as a medi...
|
|
WO/1995/021153A1 |
Phenyl acetic acid derivatives of formula (I) in which the components and index have the following meanings: X is NOCH3, CHOCH3 CHCH3 and CHCH2CH3; R1 is hydrogen and alkyl; R2 is cyano, nitro, trifluoro methyl, halogen, alkyl and alkoxy...
|
|
WO/1995/020950A1 |
The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.
|
|
WO/1995/020567A1 |
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may ...
|
